[Cooperative effect of rhIL-2 and adriamycin-magnetic albumin microsphere targeting therapy on tumor].

AIM: To observe the synergistic inhibitory effects of rhlL-2 and adriamycin-magnetic albumin microsphere(ADM-MAM) targeting therapy on tumor and to explore their antitumor mechanism. METHODS: The antitumor activity was observed using the tumor weight as index. The killer activity of natural killer (NK) cells and the lymphocyte transformation were examined by the LDH release assay and MTT colori-metry, respectively. The apoptosis of tumor cells and the expressions of p53, Fas and FasL were examined by flow cytometry. The expressions of IL-2 and IL-12 were determined by RT-PCR. RESULTS: Compared with the control group, in ADM-MAM targeting therapy group and combination therapy (ADM-MAM and rhlL-2 therapy) group, tumor weight, killer activity of NK cells, and the lymphocyte transformation; were obviously decreased: while the expression of Fas, FasL, IL-2 and IL-12 were markedly increased. CONCLUSION: ADM-MAM targeting therapy exerts anti-tumor effects with fewer side effects, which can be enhanced when combined with rhlL-2 therapy. Such synergistic anti-tumor effects may be realized by stimulating the proliferation of T cells and growth of NK cell to enhance cellular immunologic function.